The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...

With the approach of fall likely bringing the usual uptick in respiratory illness, the provincial government is boosting its ...

RSV is the leading cause of hospitalization in US infants, and in August 2023, the CDC’s vaccine advisory group recommended ...